Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer.

Young-Ju Jeong, Jin-Gu Bong, Sung-Hwan Park, Jung-Hye Choi, Hoon-Kyu Oh
Author Information
  1. Young-Ju Jeong: Department of Surgery, Catholic University of Daegu School of Medicine, Daegu, Korea.

Abstract

PURPOSE: Adipocytokines, such as leptin, resistin, and adiponectin, are associated with obesity and breast cancer. Several studies have indicated that adipocytokines may influence tumor growth or differentiation. The aims of this study were to determine the expression of leptin, leptin receptor (ObR), adiponectin and adiponectin receptor (AdipoR) in human breast cancer, to evaluate their prognostic significance in the breast cancer.
METHODS: Specimens from 198 patients with primary breast cancer were enrolled, and representative paraffin tumor blocks were selected for constructing tissue microarrarys (TMA). Immunohistochemical staining for leptin, ObR, adiponectin, and AdipoR was performed using TMA, and the clinicopathologic characteristics were evaluated from the patient's medical records.
RESULTS: Stage 0 breast cancer accounted for 41 cases, and 157 cases were invasive cancer. Positive rates of leptin and ObR expression in the ductal carcinoma in situ (DCIS) group were significantly higher than those of the invasive cancer group (97.4% vs. 34.0%, p<0.001; 74.4% vs. 29.8%, p<0.001). However, positive rates of adiponectin and AdipoR expression in the invasive cancer group were significantly higher than those in the DCIS group (53.7% vs. 33.3%, p=0.024; 59.9% vs. 26.3%, p<0.001). High leptin expression was significantly associated with high Ki-67 expression (p=0.016). High adiponectin expression was significantly correlated with smaller tumor size (p=0.001).
CONCLUSION: We suggest that losses of leptin and ObR expression could be associated with invasive cancer, whereas high adiponectin and AdipoR expression may be associated with breast cancer invasiveness.

Keywords

References

  1. Cell. 1995 Dec 29;83(7):1263-71 [PMID: 8548812]
  2. Breast Cancer Res Treat. 2006 Jul;98(2):121-32 [PMID: 16752079]
  3. Clin Exp Metastasis. 2009;26(3):197-204 [PMID: 19112600]
  4. Maturitas. 2009 Jul 20;63(3):253-6 [PMID: 19524379]
  5. Cytokine Growth Factor Rev. 2009 Jun;20(3):193-201 [PMID: 19520599]
  6. Med Oncol. 2007;24(4):361-6 [PMID: 17917082]
  7. Nature. 1994 Dec 1;372(6505):425-32 [PMID: 7984236]
  8. Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [PMID: 10092513]
  9. Clin Cancer Res. 2003 Nov 15;9(15):5699-704 [PMID: 14654554]
  10. Clin Cancer Res. 2004 Jul 1;10(13):4325-31 [PMID: 15240518]
  11. Histopathology. 2008 Oct;53(4):484-7 [PMID: 18983614]
  12. Nat Med. 2007 Mar;13(3):332-9 [PMID: 17268472]
  13. Oncol Rep. 2008 Oct;20(4):971-7 [PMID: 18813842]
  14. Endocr Relat Cancer. 2007 Jun;14(2):189-206 [PMID: 17639037]
  15. Breast Cancer Res Treat. 2007 Jul;103(3):343-8 [PMID: 17063272]
  16. J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26 [PMID: 12928347]
  17. Physiol Res. 2006;55(3):233-44 [PMID: 16238454]
  18. Cell Res. 2000 Jun;10(2):81-92 [PMID: 10896170]
  19. J Cell Physiol. 2006 Apr;207(1):12-22 [PMID: 16110483]
  20. Int J Mol Med. 2000 Apr;5(4):421-6 [PMID: 10719061]
  21. Lancet. 2004 Apr 24;363(9418):1346-53 [PMID: 15110491]
  22. Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [PMID: 16533767]
  23. J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11 [PMID: 12441326]
  24. Nutr Cancer. 2003;45(1):1-16 [PMID: 12791499]
  25. Cancer Res. 2008 Dec 1;68(23):9712-22 [PMID: 19047149]
  26. Breast Cancer Res Treat. 2010 Jan;119(2):367-7 [PMID: 19842034]
  27. Oncogene. 2009 Jul 23;28(29):2621-33 [PMID: 19483724]
  28. J Clin Endocrinol Metab. 2004 Mar;89(3):1102-7 [PMID: 15001594]
  29. J Biol Chem. 2006 Sep 8;281(36):26320-8 [PMID: 16825198]
  30. Horm Metab Res. 2007 Jan;39(1):9-13 [PMID: 17226107]